New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 22, 2014
16:11 EDTACTActavis confirms generic Neupro patent challenge
Actavis confirmed that it has filed an Abbreviated New Drug Application, or ANDA, with the FDA seeking approval to market Rotigotine Extended-release Transdermal Film, 1 mg/24 hr, 2mg/24 hr, 3 mg/24hr, 4 mg/24 hr, 6mg/24hr, and 8 mg/24 hr. Actavis' ANDA product is a generic version of UCB's Neupro, which is indicated for the treatment of signs and symptoms of idiopathic Parkinson's disease and moderate-to-severe primary Restless Legs Syndrome. UCB and LTS Lohmann Therapie-Systeme AG filed suit against Actavis' subsidiaries on August 21 in the U.S. District Court for the District of Delaware seeking to prevent Actavis from commercializing its ANDA product prior to the expiration of certain U.S. Patents. The lawsuit was filed under the provisions of the Hatch-Waxman Act, resulting in a stay of final FDA approval of Actavis' ANDA for up to 30 months from the date the plaintiffs received notice of Actavis' ANDA filing or until final resolution of the matter before the court, whichever occurs sooner, subject to any other exclusivities. Based on available information, Actavis believes it may be a "first applicant" to file an ANDA for the generic version of Neupro and, should its ANDA be approved, may be entitled to 180 days of generic market exclusivity. For the 12 months ending June 30, Neupro had total U.S. sales of approximately $85M, according to IMS Health data.
News For ACT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent ACT news | >>
November 17, 2014
09:29 EDTACTActavis to host conference call
Conference call to discuss the acquisition of Allergan will be held on November 17 at 10:30 am. Webcast Link
09:24 EDTACTAllergan up over 5% to $209 after agreeing to be acquired by Actavis
Subscribe for More Information
09:22 EDTACTOn The Fly: Pre-market Movers
Subscribe for More Information
09:21 EDTACTActavis, Allergan transaction subject to approval of shareholders of both
Subscribe for More Information
09:20 EDTACTActavis projects at least $1.8B in annual synergies from Allergan transaction
Subscribe for More Information
09:18 EDTACTActavis sees free cash flow over $8B in 2016 following Allergan acquisition
Subscribe for More Information
09:16 EDTACTActavis confirms deal to acquire Allergan for $219 in cash, stock
Subscribe for More Information
09:15 EDTACTActavis confirms deal to acquire Allergan for $219 in cash and shares
Subscribe for More Information
09:10 EDTACTActavis buying Allergan for $219 per share, CNBC reports
08:02 EDTACTActavis completes Durata Therapeutics tender offer
Subscribe for More Information
06:05 EDTACTActavis close to buying Allergan for over $64B, Bloomberg reports
Subscribe for More Information
November 16, 2014
14:02 EDTACTAllergan, Actavis move closer to deal, WSJ reports
Subscribe for More Information
November 14, 2014
16:58 EDTACTThird Point gives quarterly update on stakes
NEW STAKES: Alibaba (BABA), eBay (EBAY), Bed Bath & Beyond (BBBY), Shire (SHPG), and Parker Hannifin (PH). INCREASED STAKES: Actavis (ACT), Amgen (AMGN), EQT (EQT), Sensata (ST), Coca-Cola Enterprises (CCE). DECREASED STAKES: Williams Cos (WMB), Ally Financial (ALLY), Cheniere Energy (LNG), YPF (YPF), and FedEx (FDX). LIQUIDATED STAKES: AIG (AIG), T-Mobile (TMUS), Rackspace (RAX), Hertz (HTZ), and Citrix Systems (CTXS).
12:53 EDTACTOmega Advisors gives quarterly update on stakes
NEW STAKES: AerCap Holdings (AER), Nordic American Offshore (NAO), Melco Crown Entertainment (MPEL), Groupon (GRPN), and Ashland (ASH). INCREASED STAKES: QEP Resources (QEP), United Continental (UAL), Cabot Oil & Gas (COG), Actavis (ACT), and KAR Auction Services (KAR). DECREASED STAKES: Sprint (S), SandRidge Energy (SD), Sirius XM Holdings (SIRI), Kinder Morgan (KMI), and Transocean (RIG). LIQUIDATED STAKES: QUALCOMM (QCOM), Ocwen Financial (OCN), Freeport-McMoRan (FCX), Boston Scientific (BSX), and Capital One (COF).
07:32 EDTACTHayman Capital gives quarterly update on stakes
Subscribe for More Information
November 13, 2014
10:44 EDTACTMallinckrodt news on generic Concerta positive for Actavis, says BMO Capital
Subscribe for More Information
08:15 EDTACTActavis' sNDA for bipolar disorder candidate Saphris accepted by FDA
Subscribe for More Information
07:23 EDTACTValeant wooing doctors ahead of hoped for Allergan acquisition, WSJ says
Subscribe for More Information
November 12, 2014
10:09 EDTACTActavis in talks to buy Allergan for over $200 per share, Bloomberg says
Subscribe for More Information
10:01 EDTACTActavis in talks to buy Allergan for $60B, more than $200/share Bloomberg says
Actavis (ACT) is said to seek to pay about $200 per share, but Allergan (AGN) seeks about $210 per share, according to Bloomberg.
1 | 2 | 3 | all recent ACT news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use